Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

INTRODUCTION: Data from the SINGLE trial demonstrated that 88% of treatment-naive HIV-1 patients treated with dolutegravir and abacavir/lamivudine (DTG+ABC/3TC) achieved viral suppression at 48 weeks compared with 81% of patients treated with efavirenz/tenofovir disoproxil fumarate/emtricitabine (EF...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Siyang, Tafazzoli, Ali, Dorman, Emily, Rosenblatt, Lisa, Villasis-Keever, Angelina, Sorensen, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P073
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224816/
https://www.ncbi.nlm.nih.gov/pubmed/25394109
http://dx.doi.org/10.7448/IAS.17.4.19605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224816/
https://www.ncbi.nlm.nih.gov/pubmed/25394109
http://dx.doi.org/10.7448/IAS.17.4.19605

Ejemplares similares